Categorización de las farmacias españolas según la teoría de difusión de las innovaciones de Rogers en relación a la práctica del seguimiento farmacoterapéutico

  1. Casado de Amezúa, MJ.
  2. Martínez Martínez, F.
  3. Feletto, E.
  4. Cardero, M.
  5. Gastelurrutia, MA.
Journal:
Ars pharmaceutica

ISSN: 2340-9894,  0004-2927

Year of publication: 2011

Volume: 52

Issue: 3

Pages: 35-45

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Ars pharmaceutica

Abstract

Introduction: The aim of the study is to categorize Spanish Community Pharmacies in relation to their position in the innovation-decision process by Rogers, in relation to the provision of Medication Review with follow up. Methods: A non validated questionnaire, previously used with the same objective, was used through a CATI methodology. The dependent variables were the five different innovation/decision phases defined by Rogers [Knowledge (F-C); Persuasion (F-P); Decision (F-D); Implementation (F-I); Maintenance (F-M). Another further phase was added including pharmacists in a phase previous to knowledge (No knowledge). Pharmacies in F-M were sub categorized in relation to the number of patients receiving the service: (F-M1) from 2 to 5 patients; (F-M2) 6 to 10 patients; (F-M3) 11 to 25 patients; (F-M4) 26 to 50 patients); (F-M5) 51 to 100 and (F-M6) 101 or more patients. Pharmacies with only one patient were included in F-I. Results: 1135 answers were received (response rate = 54%). Their distribution, according to the innovation/decision process by Rogers, was as follows: No knowledge (353; 31.1%); F-C (351; 30.9%); F-P (145; 12.8%); F-D (129; 11.4%); F-I (100; 8.8%); F-M (57; 5.0%). The F-M sub categories were: F-M1 (15; 26.3%); F-M2 (12; 21.1%); F-M3 (10; 17.5%) F-M4 (10; 17.5%); F-M5 (4; 7.0%). There are huge differences among Autonomous Communities, being Aragon the one with more pharmacies located in F-I and F-M, while Cantabria shows the most high level of no-knowledge (50.0%) having a 0.0% in F-I and F-M. A 0% in F-M is also shown in La Rioja, Canarias and Asturias. The existence of a private consultation room (ZAP) is shown as a facilitator for the provision of the service, and the existence of a responsible for the service seems to be very important to the sustainability of the service after it implementation. Conclusions: However the great efforts already done by different organizations and institutions to promote the implementation and sustainability of Medication Review with follow up, according to the data obtained in this study is possible to affirm that so far this service is poorly implemented in Spain. The existence of a private consultation room (ZAP) is shown as a facilitator for the implementation of Medication Review with follow up. On the other hand the existence of a pharmacist being the responsible for the service is shown as a support to the sustainability of the service, once this has been implemented. It seems necessary to change post degree educational programs. These shouldn’t be directed only to improve knowledge, but to develop skills and competencies, what means that these programs should try to change behaviours.

Bibliographic References

  • Aguas Y, De Miguel E, Fernández-Llimós F. El seguimiento farmacoterapéutico como innovación en las farmacias comunitarias de Badajoz (España). Seguimiento Farmacoterapéutico. 2004; 3(1): 10-16.
  • Aguas Y, Fernández-Llimós F. Evaluación del “efecto cansancio” en el Programa Dáder en la provincia de Badajoz. Pharm Care Esp. 2003; 5(Extra): 119.
  • Benrimoj SI, Feletto E, Gastelurrutia MA, Martinez-Martinez F, Faus MJ. A holistic and integrated approach to implementing cognitive pharmaceutical services. Ars Pharm. 2010; 51(2): 69-88.
  • Berger BA, Grimley D. Pharmacists’ readiness for rendering pharmaceutical care. J Am Pharm Assoc (Wash). 1997; 37: 535-42.
  • Bonal J. Toda profesión tiene románticos como los que creamos la AF. Correo Farmacéutico. Semana del 14 al 20 de febrero de 2005.
  • Buisson, J. Accrediting Community Pharmacies: A way of bringing in quality standards?. Pharm J. 2002; 269: 274-5.
  • Carnes P, Koons K. Leading the next renovation: Redesigning a pharmacy structural workspace. J Am Pharm Assoc. 2010; 50: 416–8.
  • Casado de Amezúa MJ, Faus MJ, Martínez-Martínez F, Gastelurrutia MA. Opiniones de farmacéuticos que ejercen en el medio rural sobre la Atención Farmacéutica [póster]. Ars Pharm. 2008; 49(supl1): 35-46.
  • Casado de Amezúa MJ, Martinez-Martinez F, Gastelurrutia MA. Conocimiento de farmacéuticos sobre Atención Farmacéutica y barreras para la implantación del Seguimiento. VI Congreso Nacional de AF. Sevilla, Octubre de 2009.
  • Casado de Amezúa MJ, Martínez-Martínez F, Gastelurrutia MA. Opinions of pharmacists, experts in delivering advanced cognitive services such as Medicine Management, about the lack of implementation of these services in Spain. [Poster]. Pharm World Sci. 2009; 31(4): 494-508.
  • Casado de Amezúa MJ, Martínez-Martínez F, Gastelurrutia MA. Opiniones de farmacéuticos innovadores sobre el proceso de implantación del seguimiento Farmacoterapéutico en España. Ars Pharm. 2009; 50(supl1): 48-49.
  • Consejo General de Colegios de Farmacéuticos. Información estadística. En: portalfarma.org http://www.portalfarma.com/pfarma/taxonomia/general/gp000016.nsf/voDocumentos/BC90535B8D675284C12577440052FAEB/$File/Estadisticas+Colegiados+2009.pdf?OpenElement (acceso marzo, 2011)
  • Davies P, Walker AE, Grimshaw JM. A systematic review of the use of theory in the design of guideline dissemination and implementation strategies and interpretation of the results of rigorous evaluations. Davies et al. Implementation Science. 2010; 5: 14.
  • Dualde E, Faus MJ, Santonja FJ, Fernandez-Llimos.F. Effectiveness of a videoconference training course on implementing pharmacy services. Pharm World Sci. 2009; 31(6): 638-42.
  • Eriksson K, Kerem K, Nilsson D. The adoption of commercial innovations in the former Central and Eastern European markets. The case of internet banking in Estonia. Int J Bank Marketing. 2008; 26(3): 154-69.
  • Feletto E, Wilson LK, Roberts AS, Benrimoj SI.. Building capacity to implement cognitive pharmaceutical services: Quantifying the needs of community pharmacies. Res Social Adm Pharm 2010; 6(3): 163-73.
  • Ficke DL, Farris K. Use of the transtheoretical model in the medication use process. Ann Pharmacother. 2005; 39(7-8): 1.325-30.
  • Foro de AF en farmacia Comunitaria. La imagen de una farmacia orientada al paciente. Panorama Actual Med. 2010; 34: 1012-3.
  • Foro de atención farmacéutica en farmacia comunitaria, panel de expertos. Guía práctica para los Servicios de Atención Farmacéutica en farmacia comunitaria. Mayo de 2010. Ed. Consejo General de Colegios Oficiales de Farmacéuticos. Madrid. ISBN-13: 978-84-693-1717-4.
  • Foro de Atención Farmacéutica, panel de expertos. Documento de Consenso, Enero de 2008. Ed. Consejo General de Colegios Oficiales de Farmacéuticos, Madrid. ISBN 978-84-691-1243-4.
  • Gastelurrutia MA, Casado de Amezúa MJ, Gil M, Noain MA, Castrillon CC. Diferentes estrategias para impulsar el cambio en la farmacia comunitaria. Pharm Care Esp. 2009; 11: 52-62.
  • Gastelurrutia MA, Casado de Amezúa MJ, Martínez-Martínez F. Análisis de la opinión de farmacéuticos titulares de farmacias semiurbanas sobre la implantación del servicio de seguimiento farmacoterapéutico [póster]. e-Farmacéutico Comunitario. 2008; supl: 19-45.
  • Gastelurrutia MA, Casado de Amezúa MJ, Martínez-Martínez F. Percepción de los farmacéuticos sobre su futuro profesional en Atención Farmacéutica. Ed. Grupo de Investigación en Atención Farmacéutica de la Universidad de Granada. Granada, 2010. ISBN: 978-84-608-1129-9
  • Gastelurrutia MA, Faus MJ, Fernandez-Llimos F. Providing patient care in community pharmacies in Spain. Ann Pharmacother. 2005; 39(12): 2105-10.
  • Gastelurrutia MA, Fernandez-Llimos F, Benrimoj SI, Castrillon CC, Faus MJ. Barreras para la implantación de servicios cognitivos en las farmacias comunitarias españolas. Aten Primaria. 2007; 39(9): 465–72.
  • Gastelurrutia MA, Larrañaga B, Faus MJ, Martínez-Martínez F, Casado MJ. Influencia de factores organizativos internos en la Farmacia Comunitaria, para la implantación de Seguimiento Farmacoterapéutico. La opinión de los farmacéuticos adjuntos. Ars Pharm. 2008; 49(supl1): 48-49.
  • Gil MI, Cardero M, Martinez-Martinez F, Gastelurrutia MA. Priorización de Facilitadores para la gestión del cambio en la práctica de la Farmacia Comunitaria en España. VI Congreso Nacional de AF. Sevilla, octubre de 2009.
  • Grupo de Expertos. Consenso sobre atención farmacéutica. Madrid: Ministerio de Sanidad y Consumo; 2001.
  • Hepler C. A dream deferred. Am J Health-Syst Pharm. 2010; 67: 1319-25.
  • Hidalgo J, Cámara D, Baena MI, Fajardo PC, Martínez-Martínez F. Barreras para la implantación del seguimiento farmacoterapéutico en las farmacias comunitarias de Granada (España). Seguimiento Farmacoterapéutico. 2005; 3(3): 144-149.
  • Hughes CM, Hawwa AF, Scullin C, Anderson C, Bernstein CB, Björnsdóttir I, et al. Provision of pharmaceutical care by community pharmacists: a comparison across Europe. Pharm World Sci. 2010; 32: 472-87.
  • Lladós R. Hay que ofertar incansablemente el seguimiento farmacoterapéutico y por supuesto llevarlo a cabo. El Farmacéutico. 2002; 281: 48-58.
  • March JC, Puche MT, Ramos R, Arroyo L, Romero M. La Atención Farmacéutica: Médicos, Farmacéuticos y pacientes. [Póster] Gac Sanit. 2008; 22(supl 2): 9-49.
  • Martín-Calero MJ, Machuca M, Murillo MD, Cansino J, Gastelurrutia MA, Faus MJ. Structural Process and Implementation. Programs of Pharmaceutical Care in Different Countries. Curr Pharm Des. 2004; 10: 3969-85.
  • McDaniel C, Gates RH. Investigación de mercados. Cengage Learning Editores, 2005.
  • Plaza F, Díez MV. Implantación de la Atención farmacéutica. Sistemas de retribución y papel de la Administración. Pharm Care Esp. 2000; 2: 193-200.
  • Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: Toward an integrative model of change. J Consult Clin Psychol. 1983; 51: 390-5.
  • Prochaska JO, Norcross JC, DiClemente CC. Changing for good. Nueva York: Quill-Harper Collins Publishers, 2002.
  • Prochaska JO, Velicer WF, Rossi JS, Goldstein MG, Marcus BH, Rakowski W, et al. Stages of change and decisional balance for 12 problem behaviors. Health Psychol. 1994; 13: 39-46.
  • Rapport , Doel MA, Jerzembek GS. ‘‘Convenient space’’ or ‘‘a tight squeeze’’: Insider views on the community pharmacy. Health&Place. 2009; 15: 315–22.
  • Rogers EM. Diffusion of innovations. 5.ª ed. Nueva York: Free Press; 2003.
  • Rogers EM. Diffusion of preventive innovations. Addict Behav. 2002; 24: 989-93.
  • Torrecillas Navarro RA., Espejo Guerrero J. Aproximación a la situación de burnout de los farmacéuticos comunitarios rurales españoles. [abstract 141] Farmacéuticos Comunitarios. 2010; (supl1): S23-S80.
  • Valente TW, Davis RL. Accelerating the diffusion of innovations using opinion leaders. Ann Am Acad Polit Soc Sci. 1999; 566: 55-58.
  • Willink DP, Isetts BJ. Becoming indispensable: Developing innovative Community Pharmacy practices. J Am Pharm Assoc. 2005; 45: 376-89.
  • Zardain E, del Valle MO, Loza MI, García E, Lana A, Markham WA, et al. Psychosocial and behavioural determinants of the implementation of Pharmaceutical Care in Spain. Pharm World Sci. 2009; 31: 174–82.
Data source: Dialnet